Impella Sales Drive Abiomed F2016 Q2 Revenues Up 47%

Abiomed’s Protected PCI initiative, an effort to make the company’s Impella line of percutaneous heart pumps part of the standard of care for intervention in high risk patients, is off to a good start with 70% procedure growth in the US during the second fiscal quarter of 2016.